Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Oncology Reports is a distinguished journal dedicated to advancing knowledge in the field of oncology. Published by Spandidos Publications Ltd, this journal has been a cornerstone in cancer research since its establishment in 1994 and is set to continue its impactful contributions until 2024. With ISSN 1021-335X and E-ISSN 1791-2431, it ranks in the Q2 category in Cancer Research, Medicine (Miscellaneous), and Oncology as of 2023, reflecting its solid standing in the academic community. The journal's current Scopus rankings position it notably within Medicine (Oncology) (#74/404, 81st percentile) and Biochemistry, Genetics and Molecular Biology (Cancer Research) (#67/230, 71st percentile), underscoring its rigorous peer-review process and the quality of its published research. Although not an open-access journal, Oncology Reports remains committed to disseminating vital information to researchers, professionals, and students, ensuring they stay at the forefront of developments in cancer studies. Its comprehensive scope promotes a multidisciplinary approach, encompassing clinical and experimental aspects of oncology, thus serving as an essential resource for those striving to understand and combat cancer.

The Journal of the National Comprehensive Cancer Network (ISSN: 1540-1405, E-ISSN: 1540-1413) is a premier publication in the field of oncology, established by HARBORSIDE PRESS and running since 2003. This highly respected journal holds a remarkable Q1 ranking in both Medicine (Miscellaneous) and Oncology categories, showcasing its significant influence and contribution to cancer research, with a Scopus ranking placing it within the top 5% of its field (Rank #20 out of 404). Aimed at a diverse audience including researchers, clinicians, and students, the journal publishes a wide range of articles that explore cutting-edge findings, clinical practices, and evidence-based guidelines in cancer care. With its commitment to advancing the understanding and treatment of cancer, it serves as a vital resource for professionals dedicated to improving patient outcomes. Although it does not currently offer open access, its impactful content continues to be a cornerstone for anyone involved in oncology research and practice.

Onkologie is a peer-reviewed academic journal published by SPRINGER HEIDELBERG, focusing on the evolving fields of Oncology and Hematology. Established as a significant platform for the dissemination of research in these crucial areas of medicine, Onkologie aims to provide insights into the latest advancements, therapeutic strategies, and clinical practices that shape patient care in oncology and hematology. Despite its current placement in the Q4 category for both disciplines, this journal aspires to foster scholarly dialogues and enhance its contributions to the scientific community. The journal is based in Germany and encourages submissions that promote a deeper understanding of oncology's complex landscape, ensuring that researchers, clinicians, and students have access to a wealth of knowledge essential for clinical practice and further research. With an ISSN of 2731-7226 and E-ISSN of 2731-7234, Onkologie is committed to maintain high standards in publication and peer review, driving innovation and discovery in the fields it represents.

Onkologija is a distinguished open-access journal dedicated to the field of oncology, published by the Institute of Oncology Ljubljana. With its ISSN 1408-1741 and E-ISSN 1581-3215, this journal has become a crucial platform for researchers and healthcare professionals since its transition to open-access in 2008, allowing widespread dissemination of critical findings and innovations in cancer research and treatment. Located in Ljubljana, Slovenia, the journal aims to bridge the gap between clinical practice and research by publishing high-quality original articles, reviews, and case studies that address pivotal issues in oncology. Although specific metrics such as HIndex and Scopus ranks are currently unavailable, Onkologija’s commitment to advancing oncology knowledge is evident in its engaging publications that attract a diverse readership, making it an essential resource for anyone invested in the battle against cancer.

Practical Radiation Oncology is a premier journal published by Elsevier Science Inc., focusing on the critically important fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an ISSN of 1879-8500, this journal serves as an essential resource for professionals and researchers dedicated to advancing the practice and research of radiation oncology. Established in 2011 and continuing through 2024, it has quickly gained recognition, achieving a prestigious Q2 ranking in Oncology and an exceptional Q1 ranking in Radiology, Nuclear Medicine, and Imaging as of 2023. The journal, housed in New York, USA, provides a platform for innovative research and practical insights, aimed at enhancing therapeutic practices and improving patient outcomes. As part of its commitment to fostering scientific dialogue, it also features a range of articles, reviews, and clinical studies that cater to the diverse interests of its readers. Hard-copy availability combined with digital access ensures a broad reach for the latest advancements in the field.

The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

Familial Cancer is a premier journal dedicated to advancing the understanding of hereditary cancer, published by Springer. With an ISSN of 1389-9600 and E-ISSN 1573-7292, this journal serves as an essential platform for researchers and clinicians focused on the genetic predispositions to cancer and the implications for patient care. Since its inception in 2001, Familial Cancer has built a strong reputation, being consistently ranked in the Q2 category across several key research areas including Cancer Research, Genetics, and Oncology. As of 2023, it holds significant Scopus rankings, reflecting its impactful contributions in the fields of Medicine and Genetics, with a focus on clinical applications. The journal does not currently offer Open Access, emphasizing the commitment to rigorous peer review and high-quality publications. It is vital for emerging researchers and seasoned professionals alike, providing insights into the hereditary aspects of cancer and fostering developments that can lead to better prevention and therapeutic strategies.

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.